Imjudo
What Imjudo is used for
Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Imjudo
- Active substance
- tremelimumab
- Disease area
- Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX20
- Marketing authorisation holder
- AstraZeneca AB
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Imjudo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imjudo used for?
Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.
What is the active substance in Imjudo?
Imjudo contains tremelimumab.
Who makes Imjudo?
The EU marketing authorisation holder is AstraZeneca AB.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU